Predictive Value of a mRNA Signature & Liquid Biopsy in Diffuse Large B

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04670029` - Impact of an APA Program on EFS in Patients With Diffuse Large-cell B Lymphoma Treated in 1st Line	Phase 3
Active, not recruiting	`NCT04572763` - Copanlisib Plus Venetoclax in R/R DLBCL	Phase 1/Phase 2
Active, not recruiting	`NCT04526834` - Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma	Phase 1
Recruiting	`NCT03676504` - Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR	Phase 1/Phase 2
Recruiting	`NCT05365659` - IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas	Phase 1
Completed	`NCT03287817` - CD19/22 CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma	Phase 1/Phase 2
Enrolling by invitation	`NCT05645744` - Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.
Completed	`NCT04316624` - A Study of C-CAR066 in Subjects With r/r Diffuse Large B Cell Lymphoma Who Received CD19 CAR-T Therapy	Phase 1
Active, not recruiting	`NCT04555811` - FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL	Phase 1
Terminated	`NCT04189952` - Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma	Phase 2
Recruiting	`NCT01949818` - Treatment of Diffuse Large B Cell Lymphoma	Phase 4
Completed	`NCT01459887` - Study of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody to Treat Non-hodgkin's Lymphoma	Phase 3
Completed	`NCT03242902` - To Decrease Fatigue With Light Therapy	Phase 3
Recruiting	`NCT04104776` - A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas	Phase 1/Phase 2
Recruiting	`NCT05018520` - The Safety and Effectiveness of 4R-CHOP+4R vs 6R-CHOP+2R in Newly Diagnosed Patients With DLBCL in Low Risk	Phase 3
Withdrawn	`NCT04052061` - QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma	Phase 1
Recruiting	`NCT05020392` - Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma	Phase 3
Recruiting	`NCT05006716` - A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies	Phase 1/Phase 2
Completed	`NCT03297424` - A Study of PLX2853 in Advanced Malignancies.	Phase 1
Recruiting	`NCT04545762` - Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma	Phase 1

NCT number	NCT04423549
Study type	Observational
Source	Sun Yat-sen University
Contact	Qing qing Cai, MD
Phone	0086-20-87342823
Email	caiqq@sysucc.org.cn
Status	Recruiting
Phase
Start date	June 2020
Completion date	June 2021

Predictive Value of a mRNA Signature and Liquid Biopsy in Diffuse Large B Cell Lymphoma

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms